Clinical Trial Update: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing galeterone to enzalutamide in men with AR-V7–expressing metastatic castration-resistant prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Galeterone (galeterone)

Snippet

Sponsor: LTN PHARMACEUTICALS, INC. | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED